Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 7/20 | 0.55 |
| ▸ | CA2 | P00918 | 7/20 | 0.55 |
| ▸ | CA12 | O43570 | 6/20 | 0.55 |
| ▸ | CA9 | Q16790 | 6/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | STK17B | O94768 | 1/20 | 0.43 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7074276 | 0.98 | TDP1 (0.71) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL7080001 | 0.98 | TDP1 (0.71) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL7081323 | 0.98 | TDP1 (0.71) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL10431151 | 0.98 | TDP1 (0.71) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL1263135 | 0.98 | TDP1 (0.71) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL166207 | 0.94 | TDP1 (0.65) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL3020258 | 0.90 | TDP1 (0.81) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL15058382 | 0.89 | TDP1 (0.59) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL5474431 | 0.88 | TDP1 (0.54) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL136815 | 0.88 | TDP1 (0.85) | TDP1MEN1KMT2AGAAMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111825695-B | Oxazolidinone compound, preparation method, application and pharmaceutical composition thereof | 中国科学院上海药物研究所 | 2022-04-12 | — | — | CN | claimed |
| US-20210330678-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-28 | — | — | US | claimed |
| EP-3846808-A2 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-07-14 | — | — | EP | claimed |
| CN-111825695-A | Oxazolidinone compound, preparation method, application and pharmaceutical composition thereof | 中国科学院上海药物研究所 | 2020-10-27 | — | — | CN | claimed |
| US-9949966-B2 | Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMAN-LA ROCHE INC. (US) | 2018-04-24 | — | — | US | claimed |
| EP-3099685-B1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2018-04-18 | — | — | EP | claimed |
| EP-3099685-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2016-12-07 | — | — | EP | claimed |
| US-20160296515-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2016-10-13 | — | — | US | claimed |
| US-9458153-B2 | Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-10-04 | — | — | US | claimed |
| US-20160207914-A9 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-07-21 | — | — | US | claimed |
| WO-2015113990-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2015-08-06 | — | — | WO | claimed |
| US-20150210682-A1 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-07-30 | — | — | US | claimed |
| EP-1140895-B1 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-03-24 | — | — | EP | claimed |
| WO-2003018019-A2 | NEW USE OF CYCLIC COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-06 | — | — | WO | claimed |
| EP-1140895-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | claimed |
| EP-0639566-B1 | CYCLIC COMPOUND | SANTEN PHARMACEUTICAL CO LTD (JP) | 2001-06-20 | — | — | EP | claimed |
| WO-2000040576-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | claimed |
| US-5461158-A | Immunodeficiency and autoimmune diseases | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1995-10-24 | — | — | US | claimed |
| EP-0639566-A1 | CYCLIC COMPOUND | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1995-02-22 | — | — | EP | claimed |
| EP-0252030-A2 | Derivatives of L-amino acyl L-carnitine, process for their preparation and pharmaceutical compositions having hepatoprotecting activity containing same | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1988-01-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210682-A1 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HAVCR2, HCCS, DHX15 | TDP1 4336/4885MEN1 3039/4885KMT2A 2222/4885 |
| US-20210330678-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | PARP15, PAPSS1, PGA5 | TDP1 51/4885MEN1 3710/4885KMT2A 3582/4885 |
| US-20160207914-A9 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HAVCR2, HCCS, DHX15 | TDP1 4336/4885MEN1 3039/4885KMT2A 2222/4885 |
| US-20160296515-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, HCCS, DHX15 | TDP1 4336/4885MEN1 3039/4885KMT2A 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.